to tissue...

to tissue...

In research theme 2 we focus on optical and mass spectroscopy technologies for analysing tissue. We aim at developing, extending and validating these technologies for diagnostic applications.

WP2.1 Developing 3D digital pathology
Work package 2.1

Digital platforms for interpreting and managing two dimensional pathology images already exist. These digital environments improve the efficiency and quality of diagnosis in the pathologist’s workflow.  As 3D imaging is an increasingly important tool in this field, we anticipate a need for an adjusted platform. We will work on such a 3D imaging platform that will provide pathologists with an improved view on cell and tissue morphology. Initially the 3D imaging platform will encompass high resolution brightfield imaging, further on in the project a fluorescence imaging modality will be added.

Work package leader(s): 
Bas Hulsken, Dr.
Sjoerd Stallinga, Dr.
Contact: 
Bas Hulsken, Dr.
WP2.2 Clinical diagnostics applications of 2D Digital Pathology
Work package 2.2
WP2.2 Clinical diagnostics applications of 2D Digital Pathology

For diseases like breast cancer, bone cancer and cardiovascular disease, tissue imaging provides key insights for therapeutic decisions. In this work package we will further develop a 2D digital pathology platform for tissue images. We will work on establishing clinical utility and developing and validating applications.

Work package leader(s): 
Hans Morreau, Prof. dr.
Jelte Vink, Dr.
John Foekens, Prof. dr.
Mat Daemen, Prof. dr.
Contact: 
Jelte Vink, Dr.
WP2.3 Imaging mass spectrometry
Work package 2.3
WP2.3 Imaging mass spectrometry

Many diseases are associated with variations in the amount of certain proteins as well as their distribution in cells and tissue. While conventional mass spectrometry (MS) measures the molecular content, Imaging MS can also be used for analysing the distribution. We will develop and implement a new high throughput imaging mass spectrometer and integrate it with existing mass spectrometry. With this technology we will analyse samples of patients with cardiovascular diseases, cancer and neurodegenerative disorders. 

Figure: Imaging mass spectrometry shows the distribution of biomarkers with different colours in tissue (top) and the mass spectra of different regions (bottom).

Work package leader(s): 
Liam McDonnell, Prof. dr.
Achievements: 
09/12/2014